Research programme: small molecule therapeutics - Beactica/Janssen
Latest Information Update: 28 Jan 2021
At a glance
- Originator Beactica; Janssen Pharmaceutica
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Unspecified in Belgium
- 31 Jan 2019 Early research development is ongoing Belgium in an Unspecified indication
- 31 Jan 2019 Research programme: small molecule therapeutics is available for licensing as of 31 Jan 2019. http://www.beactica.com/pipeline